时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
As a result, it remains unclear who benefits, why they benefit, and how to make results repeatable [–].；Yet “one size fits all” dosing remains common, with little adjustment mid-course.；Trial issues – blinding challenges, mixed endpoints, and uneven timing windows – further weaken signal and generalizability.
方法
The protocol should prespecify assessment of blinding success using treatment-allocation guess questionnaires completed by participants and relevant study personnel [, ].；Exclusion criteria should include uncontrolled epilepsy, untreated pneumothorax, severe carbon dioxide retention, and other protocol-defined conditions associated with unacceptable HBOT risk [].；Secondary outcomes may include changes in epigenetic-age measures, targeted proteomic and metabolomic scores, HRV and sleep metrics, and patient-reported outcomes, with an a priori endpoint hierarchy and multiplicity-control strategy specified in the statistical analysis plan (SAP) [, , ].；Complex combinations of pressure, duration, frequency, intermittency, and co-interventions are best evaluated within a single Master Protocol that standardizes eligibility, follow-up, quality control, and data standards across evolving arms [,
核心结论
Even when high-quality randomized controlled trials (RCTs), lower-rigor quasi-randomized studies, or specialty guidelines exist, day-to-day care still lacks personalization, biomarker support is limited, and outcomes vary widely.；Phenotypes such as high inflammation (particularly the senescence-associated secretory phenotype, SASP), endothelial dysfunction, or a mitochondrial low-energy state may respond differently to the same nominal protocol.；When early biological changes are weak or safety thresholds are being approached, clinicians often lack objective signals to increase, reduce, or pause treatment. ‖ 结论：Importantly, the CRI, PTI-based dose mapping, biomarker thresholds, and titration rules proposed here remain framework-level constructs rather than validated clinical decision limits and require prospective validation before routine clinical use.
局限
On the evidence and translation path, platform trials with adaptive randomization may help identify effective dose–combination bundles, while target-trial–oriented real-world evidence may improve generalizability and long-term outcomes.
对本项目的价值
★★☆☆☆ 方法学进展决定我们能否在有限样本下检出真实效应，属基础设施级收益。设计 multi-omics、systematic review。
全文来源
PMC JATS 全文（正文 81,851 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Precision hyperbaric oxygen therapy: a biomarker-driven framework.
- 期刊与标识：J Transl Med · PMID 42947214 · DOI 10.1186/s12967-026-08722-w
C 级证据分级：C 级（预印本 / 观点评论，非原始研究）
本文属观点/评论类文献，不是原始研究。其论点依赖于作者对既有证据的梳理与判断，不构成新的实验证据。本站标注 C 级即为此意——阅读时请把它当作「领域内的思考框架」，而非「研究发现」。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。